The common adverse effects of<unk>  with the greatest difference from placebo are dry mouth, nausea, constipation, insomnia, anxiety, tremor, and excessive sweating.<unk>  has the highest incidence of insomnia of all second-generation antidepressants, apart from desvenlafaxine. It is also associated with about 20% increased risk of headache.<unk>  raises blood pressure in some people. One study showed an average rise of 6 mm Hg in sysolic blood pressure in 10% of patients. The prescribing information notes that hypertension, sometimes severe, is observed in some people taking<unk> , both with and without pre-existing hypertension. Safety of<unk>  in people with cardiovascular conditions and its general cardiovascular safety profile remain unclear due to the lack of data. Seizure is a rare but serious adverse effect of<unk> . It is strongly dose-dependent: for the immediate release preparation, the seizure incidence is 0.4% at the dose 300–450 mg per day; the incidence climbs almost ten-fold for the higher than recommended dose of 600 mg. For comparison, the incidence of unprovoked seizure in the general population is 0.07 to 0.09%, and the risk of seizure for a variety of other antidepressants is generally between 0 and 0.5% at the recommended doses. Cases of liver toxicity leading to death or liver transplantation have been reported for<unk> . It is considered to be one of several antidepressants with greater risk of hepatotoxicity. The prescribing information warns about<unk>  triggering an angle-closure glaucoma attack. On the other hand,<unk>  may decrease the risk of development of open angle glaucoma.<unk>  use by mothers in the first trimester of pregnancy is associated with 23% increase of the odds in congenital heart defects in their children.<unk>  has rarely been associated with instances of Stevens–Johnson syndrome. Psychiatric The FDA requires all antidepressants, including<unk> , to carry a boxed warning stating that antidepressants may increase the risk of suicide in persons younger than 25. This warning is based on a statistical analysis conducted by the FDA which found a 2-fold increase in suicidal thought and behavior in children and adolescents, and 1.5-fold increase in the 18–24 age group. For this analysis the FDA combined the results of 295 trials of 11 antidepressants in order to obtain statistically significant results. Considered in isolation,<unk>  was not statistically different from placebo.<unk>  prescribed for smoking cessation results in 25% increase of the risk of psychiatric side effects, in particular, anxiety (about 40% increase) and insomnia (about 80% increase). The evidence is insufficient to determine whether<unk>  is associated with suicides or suicidal behavior. In rare cases,<unk> -induced psychosis may develop. It is associated with higher doses of<unk> ; many cases described are at higher than recommended doses. Concurrent antipsychotic medication appears to be protective. In most cases the psychotic symptoms are eliminated by reducing the dose, ceasing treatment or adding antipsychotic medication. Although studies are lacking, a handful of case reports suggest that abrupt discontinuation of<unk>  may cause antidepressant discontinuation syndrome.
Bupropion
Atomoxetine
Hydroxybupropion
Entropion
Citalopram
Duloxetine
Dapoxetine
Fluoxetine